248 results about "Major depressive disorder" patented technology

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of one or more probiotic microorganisms, or administration of a combination of orotic acid or a salt thereof and one or more probiotic microorganisms.

The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 meq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

The present invention provides a method and device for determining depressive disorders or other mental disorders related to similar brain imbalances when the combination of powers of specific frequency bands in quantitative EEG has a certain positive or negative value. The present invention performs a signal-processing task to resting EEG recording, calculates the power of two specific frequency bands, finds the combination of the powers and evaluates the result. The method can be used as quick and easy noninvasive tool for diagnosing depression related problems in different patients as separate algorithm, as a part of an EEG recording and analysis device and as a separate device.

Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

The present invention provides a method and device for determining depressive disorders or other mental disorders related to similar brain imbalances when the combination of powers of specific frequency bands in quantitative EEG has a certain positive or negative value. The present invention performs a signal-processing task to resting EEG recording, calculates the power of two specific frequency bands, finds the combination of the powers and evaluates the result. The method can be used as quick and easy noninvasive tool for diagnosing depression related problems in different patients as separate algorithm, as a part of an EEG recording and analysis device and as a separate device.

The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.

The invention provides a depression monitoring device for depressive disorder of the elderly people. The depression monitoring device at least comprises a mobile terminal, a detector and a cloud server, wherein the mobile terminal is used for automatically collecting and / or inputting actual emotional state information by a user; the detector is used for collecting body signals by a method of beingindirectly or directly in contact with a body of the user, and the body signals are sent to the cloud server through the mobile terminal; and the cloud server is used for determining the theoreticaldepression state information corresponding to the body signals by using a depression state analysis algorithm based on the preset database. The depression monitoring device is characterized in that the cloud server is based on actual emotional state information and the body signals of the user, and / or external conditions to analyze variation trends of depression state, and when the state variationtrends of the cloud server in the state of depression exceeds the threshold at a foreseeable point-in-time, the mobile terminal sends to an alert prompt and / or activity suggestion to the current useror the associated mobile terminal. The depression monitoring device can accurately monitor the variation trends of the depression state of the user, thereby effectively reminding and guiding.